Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01893801 · ClinicalTrials.gov registry record · Phase 1
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
A Phase 1 study of Stage IV Pancreatic Cancer, sponsored by Pancreatic Cancer Research Team.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT01893801 is a Phase 1 study of Stage IV Pancreatic Cancer that has completed, run by Pancreatic Cancer Research Team. The registered enrollment target is 25 participants, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (68% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01893801, a Phase 1 study of Stage IV Pancreatic Cancer, has completed, sponsored by Pancreatic Cancer Research Team.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG nab-paclitaxel
- DRUG gemcitabine
Study Locations (3)
Arizona
- Scottsdale Health Care - Scottsdale
New Jersey
- Rutgers - Cancer Institute of New Jersey (CINJ) - New Brunswick
Pennsylvania
- Vita Medical Associates, PC - Bethlehem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-05 |
| Est. Completion | 2017-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01893801
The ClinicalTrials.gov registry entry for NCT01893801 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Pancreatic Cancer Research Team, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT01893801 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, New Jersey, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01893801 about?
NCT01893801 is a clinical study titled "Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA". The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).
What is the current status of trial NCT01893801?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2013-05. Estimated completion is 2017-10-01.
What conditions does trial NCT01893801 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer.
What interventions are being tested in trial NCT01893801?
The interventions under investigation include: Cisplatin (DRUG), nab-paclitaxel (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01893801?
This trial is sponsored by Pancreatic Cancer Research Team, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01893801 being conducted?
This trial has 3 study locations across Arizona, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
COMPLETED · Phase 1
-
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.